Magazine article Clinical Psychiatry News
Thyroid Hormone T3 Doesn't Boost Effectiveness of SSRIs: Clash with APA Guidelines. (American Psychiatric Association)
PHILADELPHIA -- The thyroid hormone T3, when taken along with a selective serotonin reuptake inhibitor, provides no extra benefits for patients with major depression, according to a study that was presented at the annual meeting of the Endocrine Society.
The study results do not support the current guidelines of the American Psychiatric Association, which state that T3 supplementation "may increase effectiveness of antidepressant medications," noted Dr. Eric Fliers of the University of Amsterdam.
"The efficacy of T3 comedication [for the treatment of major depression] has been studied only in combination with tricylic antidepressants, and the evidence has been derived exclusively from relatively small clinical trials," Dr. Fliers said. "This is the first study of T3 and an SSRI."
In this prospective, randomized, placebo-controlled pilot study, 106 men and women with major depressive disorder and a baseline Hamilton Rating Scale for Depression (HRSD) score of 16 received 8 weeks of double-blind outpatient treatment with T3 low dose (25 g), T3 high dose (50 g), or placebo, in addition to paroxetine (Paxil) 30 mg/ day, Dr. …